The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Novartis, U.S. Partner Plan Remote Trials to Boost Participation

Novartis, U.S. Partner Plan Remote Trials to Boost Participation

March 8, 2018 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ZURICH (Reuters)—Novartis plans up to 10 clinical trials over three years using a U.S. partner’s mobile technology to help free patients from burdensome hospital trips as the Swiss drugmaker aims to boost study participation and cut costs.

You Might Also Like
  • Novartis Signs $170 Million Immuno-Oncology Pact with Surface
  • Novartis to Shut U.S. Generics Plant, Cut 450 Jobs
  • Anthem May Trim Obamacare Participation in 2018
Also By This Author
  • FDA’s Gottlieb Eyes PBM Consolidation Impact on Generic Entry: CNBC

Novartis said on Wednesday it would work with Science 37, a California-based company that provides technology including smart phone apps to patients, allowing video-based telemedicine visits rather than always requiring physical travel to clinics.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Novartis Chief Executive Vas Narasimhan, who took over the Basel-based company on Feb. 1, has outlined plans to deploy more technology and leverage data to trim costs amid broad industry concern over sluggish returns on research and development investment. (http://reut.rs/2Hbi4Bm)

Science 37’s “remote trial” technology may also help remedy limitations on recruiting participants, Novartis said, citing estimates that only 2 percent of the eligible U.S. population now joins studies due to access hurdles.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Novartis aims to run studies in ways that overcome many of the barriers patients face when deciding whether or not to enroll in clinical trials, like long journeys or extensive time spent at hospitals or trial sites,” said Rob Kowalski, Novartis’s interim drug development chief.

Novartis owns 10 percent of Science 37 after participating last April in a $29 million financing round with others including Sanofi and Amgen. Further investors in Science 37, founded by Noah Craft and Belinda Tan in 2014, include Google’s GV venture firm.

 

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Pharma Co. News Tagged With: Novartis, remote trials, Science 37, video-based telemedicine

You Might Also Like:
  • Novartis Signs $170 Million Immuno-Oncology Pact with Surface
  • Novartis to Shut U.S. Generics Plant, Cut 450 Jobs
  • Anthem May Trim Obamacare Participation in 2018
  • FDA Rejects Novartis Bid to Repurpose Inflammation Drug for Heart Attacks

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)